Medscape is available in 5 Language Editions – Choose your Edition here.


Alpha Thalassemia

  • Author: Alexandra C Cheerva, MD, MS; Chief Editor: Hassan M Yaish, MD  more...
Updated: Jun 27, 2016


The alpha thalassemia (α-thalassemia) syndromes are a group of hereditary anemias of varying clinical severity. They are characterized by reduced or absent production of 1 or more of the globin chains of which human hemoglobin is composed.

The oxygen carrying capability of the red blood cells (RBCs) relies on hemoglobin, a tetramer protein that comprises 4 globin chains bound to the heme molecule. There are 4 major types of globins: alpha (α), beta (β), gamma (γ), and delta (δ). The dominant hemoglobin in adults (hemoglobin A) is composed of 2 alpha and 2 beta chains. Two minor forms of hemoglobin constitute a small percentage of normal blood: hemoglobin F (fetal), composed of 2 alpha chains and 2 gamma chains, and hemoglobin A2, composed of 2 alpha chains and 2 delta chains.

A very tightly controlled globin chain production process keeps the ratio of alpha chains to non-alpha chains at 1.00 (± 0.05). Thalassemia, by altering this process, disrupts this ratio. Decreased production of alpha-globin gene products, whether alpha1 globin or alpha2 globin (alpha-globin gene is present in duplicate on chromosome 16), yields a relative excess of beta chains, which results in less stable chains; this leads to the clinical disease known as alpha thalassemia.[1, 2] Similarly, impaired production of beta-globin gene products manifests with a more severe disease known as beta thalassemia.[3, 4]

Thalassemia is one of the world’s most common single-gene disorders. Individuals with thalassemia syndrome are most often of African, Asian, Mediterranean, or Middle Eastern descent. Mutations and gene deletions causing the various thalassemia genotypes have arisen independently in different populations but have subsequently propagated by means of natural selection.[5, 6, 7]

Thalassemia is more prevalent in regions in which malaria is endemic because the RBC phenotype confers some protection against malaria.[8] Individuals with beta thalassemia syndromes have somewhat better protection against malaria than individuals with alpha thalassemia syndromes.



Genes that regulate both the synthesis and the structure of different globins are organized into 2 separate clusters. The alpha-globin genes are encoded on chromosome 16, and the gamma-, delta-, and beta-globin genes are encoded on chromosome 11. Healthy individuals have 4 alpha-globin genes, 2 on each chromosome 16 (αα/αα; see the image below). Alpha thalassemia syndromes are caused by deficient expression of 1 or more of the 4 alpha-globin genes on chromosome 16 and are characterized by absent or reduced synthesis of alpha-globin chains.

Alpha-chain genes in duplication on chromosome 16 Alpha-chain genes in duplication on chromosome 16 pairing with non-alpha chains to produce various normal hemoglobins.

Abnormal production of alpha-globin chains results in a relative excess of gamma-globin chains in fetuses and newborns and of beta-globin chains in children and adults. Furthermore, the beta-globin chains are capable of forming soluble tetramers (β4, or hemoglobin H [HbH]); yet this form of hemoglobin is unstable and tends to precipitate within the cell, forming insoluble inclusions (Heinz bodies) that damage the red cell membrane.

In addition, diminished hemoglobinization of individual red blood cells results in damage to erythrocyte precursors and ineffective erythropoiesis in the bone marrow, as well as hypochromia and microcytosis of circulating red blood cells.

From a genetic standpoint, alpha thalassemia syndromes are extremely heterogeneous; however, their phenotypic expression may be described in simplified clinical terms related to the number of inherited alpha-globin genes. Alpha thalassemia may be broadly classified according to whether the loss of alpha-globin genes is complete or partial—that is, alpha(0) thalassemia or alpha(+) thalassemia. Some subclasses are present within the latter category, based on the number of genes affected. In all, there are four general forms of alpha thalassemia.

Alpha(0) thalassemia

More than 20 different genetic mutations resulting in the functional deletion of both pairs of alpha-globin genes (--/--) have been identified. The resulting disorder is referred to as hydrops fetalis, alpha thalassemia major, or hemoglobin Bart’s. Individuals with this disorder cannot produce any functional alpha globin and thus are unable to make any functional hemoglobin A, F, or A2. Hydrops fetalis is incompatible with extrauterine life. Fetuses with this condition die either in utero or shortly after birth because of severe anemia.

Alpha(+) thalassemia

There are more than 15 different genetic mutations that result in decreased production of alpha globin, usually through functional deletion of 1 or more of the 4 alpha-globin genes. Alpha(+) thalassemia is subclassified into the following three general forms on the basis of the number of inherited alpha genes.

Silent carrier

Persons who inherit 3 normal alpha-globin genes (-α/αα) are referred to clinically as silent carriers. Other names for this condition are alpha thalassemia minima, alpha thalassemia-2 trait, and heterozygosity for alpha(+) thalassemia minor. The affected individuals exhibit no clinical abnormalities and may be hematologically normal or have slight reductions in RBC mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH).

Alpha thalassemia trait

Inheritance of 2 normal alpha-globin genes through either heterozygosity for alpha(0) thalassemia (αα/--) or homozygosity for alpha(+) thalassemia (-α/-α) results in the development of alpha thalassemia trait, also referred to as alpha thalassemia minor or alpha thalassemia-1 trait. If both alpha2- and alpha1-globin genes are deleted on the same chromosome (--/αα), the genotype is said to have the cis form; if the 2 alpha2 -globin genes of both alleles of chromosome 16 are deleted but the alpha1 -globin genes are intact (-α/-α), it is said to have the trans form.

The affected individuals are clinically normal but frequently have minimal anemia and reduced MCV and MCH. The RBC count is usually increased, typically exceeding 5.5 × 1012/L.

Hemoglobin H disease

Inheritance of only one out of the four normal alpha-globin genes (-α/--) leads to a condition known as HbH disease, or alpha thalassemia intermedia. The loss of 3 alpha-globin genes results in abundant formation of HbH, which is characterized by a high ratio of beta globin to alpha globin and a 2-fold to 5-fold excess in beta-globin production. The excess beta chains aggregate into tetramers, which account for 5-30% of the hemoglobin level in patients with HbH disease.[9]

HbH has a high affinity for oxygen and has no Bohr effect or heme-heme interaction; therefore, it is an ineffective supplier of oxygen to the tissues under physiologic conditions. Patients with significant amounts of HbH have a defect in oxygen-carrying capacity that is more severe than would be expected on the basis of the hemoglobin concentration alone. RBCs that contain HbH are sensitive to oxidative stress; thus, they may be more susceptible to hemolysis when oxidants such as sulfonamides are administered.

Aging erythrocytes contain more precipitated HbH than younger erythrocytes; consequently, they are removed from the circulation prematurely. Thus, HbH disease is primarily a hemolytic disorder. When bone marrow cells are examined, HbH inclusions are rare, and erythropoiesis is apparently effective. Erythroid hyperplasia can result in typical structural bone abnormalities with marrow hyperplasia, bone thinning, maxillary hyperplasia, and pathologic fractures.

An Iranian study, by Farashi et al, of 66 patients with HbH disease found that point mutations produced a more severe form of the condition than did deletional mutations.[10]  The clinical severity of HbH disease may depend on which alpha-globin gene is deleted, since one of the alpha genes may produce only 25% of the alpha-globin chains, while the other provides 75% of them.



Normal hemoglobin biosynthesis requires an intact gene, silencers, enhancers, promoters, and locus control region (LCR) sequences. Several hundred mutations causing thalassemia have been described. These may affect any step in globin gene expression, transcription, pre-mRNA splicing, mRNA translation and stability, and posttranslational assembly and stability of globin polypeptides.

The most common mechanism of aberrant alpha-globin production involves deletion of either portions of the alpha-globin genes themselves or the genetic regulatory elements that control their expression. Regulatory elements may be located on the same chromosome (cis -acting elements) or on separate chromosomes (trans -acting elements).

The (--SEA) type of alpha thalassemia deletion removes both alpha-globin genes in cis, is common in Southeast Asia, and is the most common cause of HbH disease and hydrops fetalis in that part of the world. Nondeletional forms of alpha thalassemia in which the alpha-globin genes are intact are caused by mutations similar to those causing beta thalassemia and are relatively uncommon.[11, 12]

Production of functional hemoglobin is also impaired in alpha thalassemia when point mutations, frame shift mutations, nonsense mutations, and chain termination mutations occur within or around the coding sequences of the alpha-globin gene cluster. These gene-level mutations may in turn affect RNA splicing, hinder initiation of mRNA translation, or result in the generation of unstable alpha-globin chain variants.

Mutations affecting transcription, pre-mRNA splicing, or canonical splice signals are rare causes of alpha thalassemia. Other forms of alpha thalassemia are caused by either premature or failed translation termination. More rare mutations have been found to cause thalassemia by interfering with the normal folding of otherwise normal globin peptide.



United States statistics

The frequency of alpha thalassemia is low among whites. It is estimated that about 15% of American blacks are silent carriers for alpha thalassemia and about 3% have alpha thalassemia trait; HbH disease is rare in this population. In North America, many multicultural communities are growing, and these populations have increased frequencies of thalassemia syndromes.

In some ethnic groups, such as the Southeast Asian population (in particular) and Mediterranean populations, HbH disease and hemoglobin Bart’s (γ4) are common because of the frequent coinheritance of an allele lacking both alpha-globin genes and another allele lacking 1 alpha-globin gene. The high frequency of hemoglobin Constant Spring (CS) in the Southeast Asian population can lead to the HbH (--/-αCS) phenotype, which involves an elongated form of alpha-globin chain.[13, 1]

The results of one study suggested that HbH Constant Spring (HCS) should be identified as a distinct thalassemia syndrome with a high-risk of life-threatening anemia.[14] The study also found that HbH disease was managed without blood transfusions and was not associated with an increased rate of severe anemia. Because many patients with these disorders encompassed mixed ethnic backgrounds, the study emphasizes the need for extended newborn screening in populations that are customarily considered to be at low risk for HbH.[14]

According to the National Institutes of Health (NIH)-sponsored North American Thalassemia Clinical Research Network (TCRN) study of the epidemiology of thalassemia in North America, 59% of patients with alpha thalassemia have a single alpha-globin gene (-α/--), 8% have no alpha-globin genes (--/--), and 33% have gene deletions with structural mutations.

International statistics

Alpha thalassemia is perhaps the most common single-gene disorder in the world. It is estimated that there are 270 million carriers of mutant globin genes that can potentially cause severe forms of thalassemia. In addition, 300,000-400,000 severely affected infants are born every year, more than 95% of whom are in Asia, India, or the Middle East.

Before the introduction of DNA analysis, population surveys for alpha thalassemia were based entirely on the measurement of hemoglobin Bart’s levels in cord blood. However, single-gene-deletion heterozygotes do not always have detectable hemoglobin Bart’s in the neonatal period. As a result, reliable data on population frequencies for various types of alpha thalassemia are not always available.

Alpha thalassemia is common throughout parts of the world where malaria is endemic. Multiple studies have suggested that the presence of both single and double alpha-globin gene deletions has a protective effect against malaria.

The frequency of alpha thalassemia alleles is 5-10% in the Mediterranean basin, 20-30% in portions of West Africa, and as high as 60-80% in parts of Saudi Arabia, India, Thailand, Papua New Guinea, and Melanesia. In Thailand, which has a population of 62 million people, approximately 7000 infants are born each year with HbH disease. The frequency of heterozygote carrier status among the Chinese population has been reported to range from 5% to 15%. The frequency of alpha thalassemia is lower than 0.01% in Great Britain, Iceland, and Japan.[15, 16, 17, 18]

Age-related demographics

Abnormalities of alpha-globin chains are genetic, and individuals are born with the disorder. The exception to this rule is patients with alpha thalassemia myelodysplastic syndrome (ATMDS), who are usually elderly, with a mean age of 68 years at diagnosis.

Sex-related demographics

In general, males and females are equally affected. However, there is a type of alpha thalassemia that is associated with mental retardation and affects only males. This condition is referred to as alpha thalassemia mental retardation-X syndrome (ATR-X).

However, a report by Haas et al identified 2 females in a single center with ATMDS and mutations in the ATR-X gene (ATRX).[19] The investigators observed that although it was possible that females may be less likely to develop ATMDS if the inactivated copy of ATRX is reactivated throughout life, this hypothesis was ruled out in their study by the use of a cross-sectional analysis of healthy females ranging in age from neonate to 90 years to examine the pattern of ATRX inactivation.

Race-related demographics

Alpha thalassemia occurs in individuals of all ethnic backgrounds but particularly those of African, Asian, Central American, Mediterranean, and Middle Eastern descent. Emigration from regions in which carrier frequency is high increases the presence of thalassemia syndromes in other parts of the world. The North American TCRN study showed that 85% of patients with alpha thalassemia are Asian, 4% are white, and 11% are of other ethnicities, including African, black, mixed ethnicity, and unknown.



For silent carriers and individuals with alpha thalassemia trait, the prognosis is excellent.

For individuals with HbH disease, the overall survival rate varies but is generally good, with most patients surviving into adulthood. However, some patients have a more complicated course and may not do as well. Patients with HbH disease are at risk for severe anemia and have a lifelong requirement for transfusions. One study suggests that the subtype of hemoglobin H Constant Spring (HCS) is associated with a high risk of life-threatening anemia.[14] Patients identified with this subtype of HbH disease require close follow-up. If anemia is well managed and iron overload is prevented with chelation therapy, individuals with HbH disease can live long and healthy lives.

Hydrops fetalis (alpha thalassemia major) is incompatible with life and requires identification in utero and in utero transfusions if the fetus is to survive and be born. To identify fetuses with this condition, family genetic studies must be done, high-risk couples identified, and the fetus tested in utero for the absence of alpha-globin chains.

Those rare fetuses that survive to be born, with the help of intrauterine transfusions, continue to require lifelong transfusions and medical care. They may be considered for hematopoietic stem cell transplantation, which is curative of their alpha thalassemia major syndrome.

A study by Joly et al supported the idea that alpha thalassemia reduces the risk of cerebral vasculopathy in children with sickle cell anemia. The report involved three groups of children with sickle cell anemia, including one group with cerebral vasculopathy (ie, stroke, silent infarct, or abnormal transcranial Doppler ultrasonography results), a second group without cerebral vasculopathy, and a third group with conditional transcranial Doppler ultrasonography results. The data indicated that alpha thalassemia has a protective effect against, and that glucose-6-phosphate dehydrogenase (G6PD) deficiency increases the risk for, cerebral vasculopathy in sickle cell anemia.[20]


Patient Education

Patients with a family history or a known carrier state for alpha thalassemia gene mutations should obtain genetic counseling to determine the genotype and assess the risk to offspring. This is especially true in cases of suspected concomitant hemoglobinopathy.

Contributor Information and Disclosures

Alexandra C Cheerva, MD, MS Associate Professor of Pediatrics, University of Louisville School of Medicine; Director of Pediatric Blood and Marrow Transplantation, Section of Pediatric Hematology and Oncology, Kosair Children's Hospital

Alexandra C Cheerva, MD, MS is a member of the following medical societies: American Society for Blood and Marrow Transplantation, Children's Oncology Group, American Society of Clinical Oncology, International Pediatric Transplant Association, American Society of Pediatric Hematology/Oncology, Kentucky Medical Association

Disclosure: Nothing to disclose.


Abdullah Kutlar, MD Director of Sickle Cell Center, Fellowship Program Director, Professor, Department of Internal Medicine, Section of Hematology and Oncology, Medical College of Georgia, Georgia Regents University

Abdullah Kutlar, MD is a member of the following medical societies: American Society of Hematology

Disclosure: Nothing to disclose.

Ashok B Raj, MD Professor, Section of Pediatric Hematology and Oncology, Department of Pediatrics, Kosair Children's Hospital, University of Louisville School of Medicine

Ashok B Raj, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, Kentucky Medical Association, Children's Oncology Group

Disclosure: Nothing to disclose.

Jennifer L Jones-Crawford, MD Fellow, Department of Hematology/Oncology, Medical College of Georgia

Jennifer L Jones-Crawford, MD is a member of the following medical societies: American College of Physicians, American Society of Hematology

Disclosure: Nothing to disclose.

Samer A Bleibel, MD Staff Physician, Department of Internal Medicine, Wayne State University School of Medicine, St John's Hospital and Medical Centers

Samer A Bleibel, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Robert J Leonard, MD Clinical Assistant Professor, Department of Medicine, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Gary D Crouch, MD Associate Professor, Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Uniformed Services University of the Health Sciences

Gary D Crouch, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology

Disclosure: Nothing to disclose.

Chief Editor

Hassan M Yaish, MD Medical Director, Intermountain Hemophilia and Thrombophilia Treatment Center; Professor of Pediatrics, University of Utah School of Medicine; Director of Hematology, Pediatric Hematologist/Oncologist, Department of Pediatrics, Primary Children's Medical Center

Hassan M Yaish, MD is a member of the following medical societies: American Academy of Pediatrics, New York Academy of Sciences, American Medical Association, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Michigan State Medical Society

Disclosure: Nothing to disclose.

Additional Contributors

Marcel E Conrad, MD Distinguished Professor of Medicine (Retired), University of South Alabama College of Medicine

Marcel E Conrad, MD is a member of the following medical societies: Alpha Omega Alpha, American Association for the Advancement of Science, American Association of Blood Banks, American Chemical Society, American College of Physicians, American Physiological Society, American Society for Clinical Investigation, American Society of Hematology, Association of American Physicians, Association of Military Surgeons of the US, International Society of Hematology, Society for Experimental Biology and Medicine, SWOG

Disclosure: Partner received none from No financial interests for none.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Afshin Ameri, MD, and Linda K Hendricks, MD,to the development and writing of the source articles.

  1. Chui DH. Alpha-thalassemia: Hb H disease and Hb Barts hydrops fetalis. Ann N Y Acad Sci. 2005. 1054:25-32. [Medline].

  2. Piel FB, Weatherall DJ. The a-thalassemias. N Engl J Med. 2014 Nov 13. 371(20):1908-16. [Medline].

  3. Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician. 2009 Aug 15. 80(4):339-44. [Medline].

  4. Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci. 2009 Apr. 66(7):1154-62. [Medline].

  5. Yu J, Xie J, Luo L, Li Z. An Alu Element-Mediated 28.5?kb a-Thalassemia Deletion Found in a Chinese Family. Hemoglobin. 2014 Nov 5. 1-4. [Medline].

  6. Deo MG, Pawar PV. Alpha thalassaemia in tribal communities of coastal Maharashtra, India. Indian J Med Res. 2014 Aug. 140(2):231-7. [Medline]. [Full Text].

  7. Marsella M, Salvagno G, Dolcini B, Ferlini A, Ravani A, Harteveld CL, et al. Characterization of Hb Calvino (HBB: c.406G?>?A): a new silent ß-globin gene variant found in coexistence with a-thalassemia in a family of African origin. Hemoglobin. 2014. 38(5):369-72. [Medline].

  8. Danquah I, Mockenhaupt FP. Alpha(+)-thalassaemia and malarial anaemia. Trends Parasitol. 2008 Nov. 24(11):479-81. [Medline].

  9. Liu YT, Old JM, Miles K, et al. Rapid detection of alpha-thalassaemia deletions and alpha-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol. 2000 Feb. 108(2):295-9. [Medline].

  10. Farashi S, Bayat N, Vakili S, et al. Point mutations which should not be overlooked in Hb H disease. Expert Rev Hematol. 2016 Jan. 9 (1):107-13. [Medline].

  11. Chan V, Yam I, Chen FE, Chan TK. A reverse dot-blot method for rapid detection of non-deletion alpha thalassaemia. Br J Haematol. 1999 Mar. 104(3):513-5. [Medline].

  12. Nainggolan IM, Harahap A, Ambarwati DD, Liliani RV, Megawati D, Swastika M, et al. Interaction of Hb Adana (HBA2: c.179G>A) with Deletional and Nondeletional a+-Thalassemia Mutations: Diverse Hematological and Clinical Features. Hemoglobin. 2013 Apr 25. [Medline].

  13. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003 Feb 1. 101(3):791-800. [Medline]. [Full Text].

  14. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med. 2011 Feb 24. 364(8):710-8. [Medline].

  15. Casas-Castaneda M, Hernandez-Lugo I, Torres O, et al. Alpha-thalassemia in a selected population of Mexico. Rev Invest Clin. 1998 Sep-Oct. 50(5):395-8. [Medline].

  16. Ko TM, Hwa HL, Liu CW, et al. Prevalence study and molecular characterization of alpha-thalassemia in Filipinos. Ann Hematol. 1999 Aug. 78(8):355-7. [Medline].

  17. Chaibunruang A, Prommetta S, Yamsri S, Fucharoen G, Sae-Ung N, Sanchaisuriya K, et al. Molecular and hematological studies in a large cohort of a0-thalassemia in northeast Thailand: Data from a single referral center. Blood Cells Mol Dis. 2013 Apr 29. [Medline].

  18. Li J, Li R, Zhou JY, Xie XM, Liao C, Li DZ. Prenatal control of nondeletional a-thalassemia: first experience in mainland China. Prenat Diagn. 2013 May 2. [Medline].

  19. Haas PS, Roy NB, Gibbons RJ, Deville MA, Fisher C, Schwabe M. The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS). Br J Haematol. 2009 Feb. 144(4):538-45. [Medline].

  20. Joly P, Garnier N, Kebaili K, et al. G6PD deficiency and absence of α-thalassemia increase the risk for cerebral vasculopathy in children with sickle cell anemia. Eur J Haematol. 2015 Jun 13. [Medline].

  21. Singer ST. Variable clinical phenotypes of alpha-thalassemia syndromes. ScientificWorldJournal. 2009 Jul 13. 9:615-25. [Medline].

  22. Bahar A, Shekarriz R, Janbabai G, Shirzad R, Aarabi M, Kashi Z. Insulin resistance, impaired glucose tolerance and alpha-thalassemia carrier state. J Diabetes Metab Disord. 2015. 14:2. [Medline].

  23. Winichakoon P, Tantiworawit A, Rattanathammethee T, et al. Prevalence and Risk Factors for Complications in Patients with Nontransfusion Dependent Alpha- and Beta-Thalassemia. Anemia. 2015. 2015:793025. [Medline]. [Full Text].

  24. Tongsong T, Srisupundit K, Luewan S. Outcomes of pregnancies affected by hemoglobin H disease. Int J Gynaecol Obstet. 2009 Mar. 104(3):206-8. [Medline].

  25. Tantiweerawong N, Jaovisidha A, Israngura Na Ayudhya N. Pregnancy outcome of hemoglobin H disease. Int J Gynaecol Obstet. 2005 Sep. 90(3):236-7. [Medline].

  26. Giambona A, Passarello C, Renda D, Maggio A. The significance of the hemoglobin A(2) value in screening for hemoglobinopathies. Clin Biochem. 2009 Dec. 42(18):1786-96. [Medline].

  27. Ribeiro DM, Sonati MF. Regulation of human alpha-globin gene expression and alpha-thalassemia. Genet Mol Res. 2008. 7(4):1045-53. [Medline].

  28. [Guideline] Gibson BE, Todd A, Roberts I, et al. Transfusion guidelines for neonates and older children. Br J Haematol. 2004 Feb. 124(4):433-53. [Medline]. [Full Text].

  29. Liu JZ, Yan M, Wang LR, et al. Molecular prenatal diagnosis of alpha-thalassemia using real-time and multiplex polymerase chain reaction methods. Hemoglobin. 2008. 32(6):553-60. [Medline].

Alpha-chain genes in duplication on chromosome 16 pairing with non-alpha chains to produce various normal hemoglobins.
Peripheral smear from patient with hemoglobin H disease showing target cells, microcytosis, hypochromia, and anisopoikilocytosis. Morphologic abnormalities are similar to those observed in beta thalassemia. In silent carriers, only mild microcytosis is observed.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.